Epidemiology, Staging, Grading, and Risk Stratification of Bladder Cancer

Marc Colombel, Mark Soloway, Hideyuki Akaza, Andreas Böhle, Joan Palou, Roger Buckley, Donald Lamm, Maurizio Brausi, J. Alfred Witjes, Raj Persad

Research output: Contribution to journalArticle

94 Citations (Scopus)

Abstract

Context: Understanding the epidemiology and risk factors for non-muscle invasive bladder cancer (NMIBC) can assist in the prevention and early detection of the disease. Furthermore, staging, grading, and risk stratification are critical for determining the most appropriate management strategies for NMIBC based on risk of recurrence and progression. Objective: To provide community urologists with an overview of the epidemiology of NMIBC as well as current approaches to staging, grading, and risk stratification. Evidence acquisition: A committee of internationally renowned leaders in bladder cancer management, known as the International Bladder Cancer Group (IBCG), identified current key influencing guidelines and published English-language literature related to the epidemiology, staging, and grading of NMIBC available as of March 2008. The IBCG met on four occasions to review the main findings of the identified literature and the current clinical practice guidelines of the European Association of Urology (EAU), the First International Consultation on Bladder Tumors (FICBT), the National Comprehensive Cancer Network (NCCN), and the American Urological Association (AUA). Evidence synthesis: Based on this review, the IBCG provided a summary on the epidemiology of NMIBC and recommendations for the staging, grading, and risk stratification of the disease. Conclusions: Urologists should record the smoking habits of patients and monitor for possible occupational exposure to urothelial carcinogens. The tumour-node-metastases (TNM) classification for tumour staging and both the World Health Organization (WHO) 1973 and 2004 grading systems should be applied for appropriate staging and grading of NMIBC. Urologists should also consider the use of the European Organisation for Research and Treatment of Cancer (EORTC) risk tables for risk stratification of NMIBC based on risk of disease recurrence and progression.

Original languageEnglish
Pages (from-to)618-626
Number of pages9
JournalEuropean Urology, Supplements
Volume7
Issue number10
DOIs
StatePublished - Oct 1 2008
Externally publishedYes

Fingerprint

Urinary Bladder Neoplasms
Epidemiology
Neoplasm Staging
Recurrence
Occupational Exposure
Practice Guidelines
Carcinogens
Habits
Disease Progression
Early Diagnosis
Neoplasms
Language
Referral and Consultation
Smoking
Guidelines
Neoplasm Metastasis

Keywords

  • Bladder cancer risk factors
  • Epidemiology
  • Grading
  • Non-muscle invasive bladder cancer
  • Risk stratification
  • Staging

ASJC Scopus subject areas

  • Urology

Cite this

Colombel, M., Soloway, M., Akaza, H., Böhle, A., Palou, J., Buckley, R., ... Persad, R. (2008). Epidemiology, Staging, Grading, and Risk Stratification of Bladder Cancer. European Urology, Supplements, 7(10), 618-626. https://doi.org/10.1016/j.eursup.2008.08.002

Epidemiology, Staging, Grading, and Risk Stratification of Bladder Cancer. / Colombel, Marc; Soloway, Mark; Akaza, Hideyuki; Böhle, Andreas; Palou, Joan; Buckley, Roger; Lamm, Donald; Brausi, Maurizio; Witjes, J. Alfred; Persad, Raj.

In: European Urology, Supplements, Vol. 7, No. 10, 01.10.2008, p. 618-626.

Research output: Contribution to journalArticle

Colombel, M, Soloway, M, Akaza, H, Böhle, A, Palou, J, Buckley, R, Lamm, D, Brausi, M, Witjes, JA & Persad, R 2008, 'Epidemiology, Staging, Grading, and Risk Stratification of Bladder Cancer', European Urology, Supplements, vol. 7, no. 10, pp. 618-626. https://doi.org/10.1016/j.eursup.2008.08.002
Colombel M, Soloway M, Akaza H, Böhle A, Palou J, Buckley R et al. Epidemiology, Staging, Grading, and Risk Stratification of Bladder Cancer. European Urology, Supplements. 2008 Oct 1;7(10):618-626. https://doi.org/10.1016/j.eursup.2008.08.002
Colombel, Marc ; Soloway, Mark ; Akaza, Hideyuki ; Böhle, Andreas ; Palou, Joan ; Buckley, Roger ; Lamm, Donald ; Brausi, Maurizio ; Witjes, J. Alfred ; Persad, Raj. / Epidemiology, Staging, Grading, and Risk Stratification of Bladder Cancer. In: European Urology, Supplements. 2008 ; Vol. 7, No. 10. pp. 618-626.
@article{18e6652b5d1049689872488b0924cc92,
title = "Epidemiology, Staging, Grading, and Risk Stratification of Bladder Cancer",
abstract = "Context: Understanding the epidemiology and risk factors for non-muscle invasive bladder cancer (NMIBC) can assist in the prevention and early detection of the disease. Furthermore, staging, grading, and risk stratification are critical for determining the most appropriate management strategies for NMIBC based on risk of recurrence and progression. Objective: To provide community urologists with an overview of the epidemiology of NMIBC as well as current approaches to staging, grading, and risk stratification. Evidence acquisition: A committee of internationally renowned leaders in bladder cancer management, known as the International Bladder Cancer Group (IBCG), identified current key influencing guidelines and published English-language literature related to the epidemiology, staging, and grading of NMIBC available as of March 2008. The IBCG met on four occasions to review the main findings of the identified literature and the current clinical practice guidelines of the European Association of Urology (EAU), the First International Consultation on Bladder Tumors (FICBT), the National Comprehensive Cancer Network (NCCN), and the American Urological Association (AUA). Evidence synthesis: Based on this review, the IBCG provided a summary on the epidemiology of NMIBC and recommendations for the staging, grading, and risk stratification of the disease. Conclusions: Urologists should record the smoking habits of patients and monitor for possible occupational exposure to urothelial carcinogens. The tumour-node-metastases (TNM) classification for tumour staging and both the World Health Organization (WHO) 1973 and 2004 grading systems should be applied for appropriate staging and grading of NMIBC. Urologists should also consider the use of the European Organisation for Research and Treatment of Cancer (EORTC) risk tables for risk stratification of NMIBC based on risk of disease recurrence and progression.",
keywords = "Bladder cancer risk factors, Epidemiology, Grading, Non-muscle invasive bladder cancer, Risk stratification, Staging",
author = "Marc Colombel and Mark Soloway and Hideyuki Akaza and Andreas B{\"o}hle and Joan Palou and Roger Buckley and Donald Lamm and Maurizio Brausi and Witjes, {J. Alfred} and Raj Persad",
year = "2008",
month = "10",
day = "1",
doi = "10.1016/j.eursup.2008.08.002",
language = "English",
volume = "7",
pages = "618--626",
journal = "European Urology, Supplements",
issn = "1569-9056",
publisher = "Elsevier",
number = "10",

}

TY - JOUR

T1 - Epidemiology, Staging, Grading, and Risk Stratification of Bladder Cancer

AU - Colombel, Marc

AU - Soloway, Mark

AU - Akaza, Hideyuki

AU - Böhle, Andreas

AU - Palou, Joan

AU - Buckley, Roger

AU - Lamm, Donald

AU - Brausi, Maurizio

AU - Witjes, J. Alfred

AU - Persad, Raj

PY - 2008/10/1

Y1 - 2008/10/1

N2 - Context: Understanding the epidemiology and risk factors for non-muscle invasive bladder cancer (NMIBC) can assist in the prevention and early detection of the disease. Furthermore, staging, grading, and risk stratification are critical for determining the most appropriate management strategies for NMIBC based on risk of recurrence and progression. Objective: To provide community urologists with an overview of the epidemiology of NMIBC as well as current approaches to staging, grading, and risk stratification. Evidence acquisition: A committee of internationally renowned leaders in bladder cancer management, known as the International Bladder Cancer Group (IBCG), identified current key influencing guidelines and published English-language literature related to the epidemiology, staging, and grading of NMIBC available as of March 2008. The IBCG met on four occasions to review the main findings of the identified literature and the current clinical practice guidelines of the European Association of Urology (EAU), the First International Consultation on Bladder Tumors (FICBT), the National Comprehensive Cancer Network (NCCN), and the American Urological Association (AUA). Evidence synthesis: Based on this review, the IBCG provided a summary on the epidemiology of NMIBC and recommendations for the staging, grading, and risk stratification of the disease. Conclusions: Urologists should record the smoking habits of patients and monitor for possible occupational exposure to urothelial carcinogens. The tumour-node-metastases (TNM) classification for tumour staging and both the World Health Organization (WHO) 1973 and 2004 grading systems should be applied for appropriate staging and grading of NMIBC. Urologists should also consider the use of the European Organisation for Research and Treatment of Cancer (EORTC) risk tables for risk stratification of NMIBC based on risk of disease recurrence and progression.

AB - Context: Understanding the epidemiology and risk factors for non-muscle invasive bladder cancer (NMIBC) can assist in the prevention and early detection of the disease. Furthermore, staging, grading, and risk stratification are critical for determining the most appropriate management strategies for NMIBC based on risk of recurrence and progression. Objective: To provide community urologists with an overview of the epidemiology of NMIBC as well as current approaches to staging, grading, and risk stratification. Evidence acquisition: A committee of internationally renowned leaders in bladder cancer management, known as the International Bladder Cancer Group (IBCG), identified current key influencing guidelines and published English-language literature related to the epidemiology, staging, and grading of NMIBC available as of March 2008. The IBCG met on four occasions to review the main findings of the identified literature and the current clinical practice guidelines of the European Association of Urology (EAU), the First International Consultation on Bladder Tumors (FICBT), the National Comprehensive Cancer Network (NCCN), and the American Urological Association (AUA). Evidence synthesis: Based on this review, the IBCG provided a summary on the epidemiology of NMIBC and recommendations for the staging, grading, and risk stratification of the disease. Conclusions: Urologists should record the smoking habits of patients and monitor for possible occupational exposure to urothelial carcinogens. The tumour-node-metastases (TNM) classification for tumour staging and both the World Health Organization (WHO) 1973 and 2004 grading systems should be applied for appropriate staging and grading of NMIBC. Urologists should also consider the use of the European Organisation for Research and Treatment of Cancer (EORTC) risk tables for risk stratification of NMIBC based on risk of disease recurrence and progression.

KW - Bladder cancer risk factors

KW - Epidemiology

KW - Grading

KW - Non-muscle invasive bladder cancer

KW - Risk stratification

KW - Staging

UR - http://www.scopus.com/inward/record.url?scp=51349146877&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=51349146877&partnerID=8YFLogxK

U2 - 10.1016/j.eursup.2008.08.002

DO - 10.1016/j.eursup.2008.08.002

M3 - Article

AN - SCOPUS:51349146877

VL - 7

SP - 618

EP - 626

JO - European Urology, Supplements

JF - European Urology, Supplements

SN - 1569-9056

IS - 10

ER -